ClinicalTrials.gg
CompletedNCT07397936Updated Nov 18, 2026

Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery

A Phase 4 interventional study of Rebamipide 2% ophthalmic solution and Diquafosol 3% ophthalmic solution in Dry Eye Disease (DED) and Cataract, sponsored by Samsung Medical Center. Completed at 1 site in South Korea. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Aug 2025, registered Feb 2026).
Updated Oct 27, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing rebamipide in Dry Eye Syndromes — 1 open to participants now, 1 under way, none of them phase 3. rebamipide · Dry Eye Syndromes.

Enrollment
12th of 14
56 · median 171
Started
2025
the only one that year
Phase 4
4 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
2 of 14
Samsung Medical Center

Among the 14 studies testing rebamipide in Dry Eye Syndromes, this one is the 12th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 4, and was the 13th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 14 studies testing rebamipide in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rebamipide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing rebamipide in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.

The main questions it aims to answer are:

Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?

Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.

Participants will:

Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.

Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.

Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.

Read the detailed description

Dry eye disease (DED) is common in patients undergoing cataract surgery and may worsen during the perioperative period, leading to ocular discomfort and delayed visual recovery. Pharmacologic treatments targeting tear film instability and ocular surface inflammation are therefore important in perioperative management.

This prospective, randomized, parallel-group clinical trial compared two perioperative treatment strategies for DED in patients scheduled for cataract surgery. Eligible participants with pre-existing dry eye disease were randomized in a 1:1 ratio to receive either topical rebamipide 2% monotherapy or combination therapy with topical diquafosol 3% and cyclosporine 0.05%. Study medications were initiated 1 month prior to surgery and continued for 3 months postoperatively.

The primary outcome measure was the change in tear film breakup time (TBUT) during the early postoperative period. Secondary outcome measures included changes in corneal staining graded by the Oxford scale, patient-reported symptoms assessed by the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, and ocular surface inflammation evaluated using a tear matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay.

Clinical assessments were performed at baseline, on the day of surgery, and at postoperative week 1, month 1, and month 3. Safety was evaluated by monitoring intraoperative and postoperative adverse events throughout the study period.

03

Conditions studied

  • Dry Eye Disease (DED)
  • Cataract
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults scheduled for cataract surgery
  • Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:

    • Tear film breakup time (TBUT) ≤7 seconds
    • Oxford corneal staining grade ≥1
    • Schirmer's test value ≤10 mm/5 min
  • Ability and willingness to comply with the study protocol and follow-up schedule
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
  • Use of topical intraocular pressure-lowering medications
  • History of ocular surgery other than cataract surgery in the study eye
  • Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Group R

    Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

    Drug: Rebamipide 2% ophthalmic solution

  • Active comparator
    Group DC

    Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

    Drug: Diquafosol 3% ophthalmic solution · Drug: Cyclosporine 0.05% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Tear Film Breakup Time (TBUT)

    Change in tear film breakup time (TBUT) from baseline and during the early postoperative period following cataract surgery, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy.

    Time frame: From baseline to postoperative week 1

Secondary outcomes

  1. Change in Ocular Surface Disease Index (OSDI) Score

    Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes).

    Time frame: From baseline to 1 and 3 months postoperatively

  2. Change in Corneal Staining Grade (Oxford Scale)

    Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes).

    Time frame: From baseline to postoperative week 1, and to 1 and 3 months postoperatively

  3. Change in Schirmer's Test Value

    Change in tear secretion measured by Schirmer's test without anesthesia, comparing tear production between rebamipide monotherapy and diquafosol-cyclosporine combination therapy.

    Time frame: From baseline to 1 and 3 months postoperatively

  4. Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level

    Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a point-of-care immunoassay (InflammaDry), comparing ocular surface inflammation between treatment groups.

    Time frame: From baseline to 1 and 3 months postoperatively

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No — The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in May 2026, 9 months.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 9 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Aug 2024 → Aug 2025, primary completion May 2025 → May 2026 and completion May 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Aug 1, 2025was Aug 2024
Primary completionActual
May 1, 2026was May 2025
CompletionActual
May 1, 2026was May 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2024→Aug 1, 2025
Oct 27, 2026
Primary completion
May 1, 2025→May 1, 2026
Oct 27, 2026
Study completion
May 1, 2025→May 1, 2026
Oct 27, 2026
Enrollment
55→56
Oct 27, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChange in Corneal Staining Grade (Oxford Scale): how it is measured was reworded
  • DescriptionChange in Ocular Surface Disease Index (OSDI) Score: how it is measured was reworded
Oct 27, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: identifiers
  2. Oct 27, 2026
    Start date Aug 1, 2024→Aug 1, 2025
    Primary completion May 1, 2025→May 1, 2026
    Study completion May 1, 2025→May 1, 2026
    Enrollment 55→56
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in Corneal Staining Grade (Oxford Scale): how it is measured was reworded
    • DescriptionChange in Ocular Surface Disease Index (OSDI) Score: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07397936
Responsible party
Dong Hui Lim (Associate Professor, Samsung Medical Center) — Principal investigator
First posted
Feb 9, 2026
Start date
Aug 1, 2025
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rebamipide

Start the discussion